{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:02:36Z","timestamp":1791417756160,"version":"4.3.3"},"reference-count":98,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloproliferative neoplasms (MPNs) transform to myelofibrosis (MF) and highly lethal acute myeloid leukemia (AML), although the actionable mechanisms driving progression remain elusive. Here, we elucidate the role of the high mobility group A1 (HMGA1) chromatin regulator as a novel driver of MPN progression. HMGA1 is upregulated in MPN, with highest levels after transformation to MF or AML. To define HMGA1 function, we disrupted gene expression via CRISPR\/Cas9, short hairpin RNA, or genetic deletion in MPN models. HMGA1 depletion in JAK2V617F AML cell lines disrupts proliferation, clonogenicity, and leukemic engraftment. Surprisingly, loss of just a single Hmga1 allele prevents progression to MF in JAK2V617F mice, decreasing erythrocytosis, thrombocytosis, megakaryocyte hyperplasia, and expansion of stem and progenitors, while preventing splenomegaly and fibrosis within the spleen and BM. RNA-sequencing and chromatin immunoprecipitation sequencing revealed HMGA1 transcriptional networks and chromatin occupancy at genes that govern proliferation (E2F, G2M, mitotic spindle) and cell fate, including the GATA2 master regulatory gene. Silencing GATA2 recapitulates most phenotypes observed with HMGA1 depletion, whereas GATA2 re-expression partially rescues leukemogenesis. HMGA1 transactivates GATA2 through sequences near the developmental enhancer (+9.5), increasing chromatin accessibility and recruiting active histone marks. Further, HMGA1 transcriptional networks, including proliferation pathways and GATA2, are activated in human MF and MPN leukemic transformation. Importantly, HMGA1 depletion enhances responses to the JAK2 inhibitor, ruxolitinib, preventing MF and prolonging survival in murine models of JAK2V617F AML. These findings illuminate HMGA1 as a key epigenetic switch involved in MPN transformation and a promising therapeutic target to treat or prevent disease progression.<\/jats:p>","DOI":"10.1182\/blood.2021013925","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T16:09:18Z","timestamp":1647274158000},"page":"2797-2815","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-6059","authenticated-orcid":false,"given":"Liping","family":"Li","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-409X","authenticated-orcid":false,"given":"Jung-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cope","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Center for Epigenetics Research, Memorial Sloan Kettering Cancer Institute, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Koche","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Center for Epigenetics Research, Memorial Sloan Kettering Cancer Institute, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xian","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8680-4119","authenticated-orcid":false,"given":"Li Z.","family":"Luo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1430-3128","authenticated-orcid":false,"given":"Daniel R.","family":"Matson","sequence":"additional","affiliation":[{"name":"Blood Cancer Research Institute, Department of Cell and Regenerative Biology, UW Carbone Cancer Center, University of Wisconsin School of Medicine, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhuang Joe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophelia","family":"Rogers","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-7083","authenticated-orcid":false,"given":"Matthew C.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Pharmacology, Incyte Research Institute, Wilmington, DE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Biologic Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio-Rodriguez","family":"Romero","sequence":"additional","affiliation":[{"name":"MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institutes of Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-9663","authenticated-orcid":false,"given":"Bethan","family":"Psaila","sequence":"additional","affiliation":[{"name":"MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institutes of Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry L.","family":"Spivak","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"},{"name":"Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-4317","authenticated-orcid":false,"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-7060","authenticated-orcid":false,"given":"Linda M. S.","family":"Resar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"},{"name":"Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD;"},{"name":"Cellular and Molecular Medicine Graduate Program and"},{"name":"Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2022050515305488700_B1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood."},{"issue":"5","key":"2022050515305488700_B2","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2022050515305488700_B3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood."},{"issue":"1","key":"2022050515305488700_B4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3324\/haematol.2009.015941","article-title":"Hereditary myeloproliferative disorders","volume":"95","author":"Skoda","year":"2010","journal-title":"Haematologica."},{"issue":"14","key":"2022050515305488700_B5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood."},{"issue":"16","key":"2022050515305488700_B6","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"issue":"9","key":"2022050515305488700_B7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N Engl J Med."},{"issue":"22","key":"2022050515305488700_B8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022050515305488700_B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica."},{"issue":"8","key":"2022050515305488700_B10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin Proc."},{"issue":"24","key":"2022050515305488700_B11","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv."},{"issue":"9","key":"2022050515305488700_B12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"issue":"12","key":"2022050515305488700_B13","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"issue":"20","key":"2022050515305488700_B14","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022050515305488700_B15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/hematology.2020000128","article-title":"Applied genomics in MPN presentation","volume":"2020","author":"Moliterno","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"9","key":"2022050515305488700_B16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2021","journal-title":"Blood."},{"issue":"15","key":"2022050515305488700_B17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2022050515305488700_B18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell."},{"issue":"9464","key":"2022050515305488700_B19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet."},{"issue":"7037","key":"2022050515305488700_B20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature."},{"issue":"17","key":"2022050515305488700_B21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2022050515305488700_B22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell."},{"issue":"9","key":"2022050515305488700_B23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica."},{"issue":"6465","key":"2022050515305488700_B24","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science."},{"issue":"11","key":"2022050515305488700_B25","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2V617F-mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov."},{"issue":"6","key":"2022050515305488700_B26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"2022050515305488700_B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semcancer.2012.12.001","article-title":"Higher order chromatin organization in cancer","volume":"23","author":"Reddy","year":"2013","journal-title":"Semin Cancer Biol."},{"issue":"8","key":"2022050515305488700_B28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1158\/0008-5472.CAN-17-3045","article-title":"Lessons from the crypt: HMGA1-amping up Wnt for stem cells and tumor progression","volume":"78","author":"Resar","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"2022050515305488700_B29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/0008-5472.CAN-09-1212","article-title":"The high mobility group A1 gene: transforming inflammatory signals into cancer?","volume":"70","author":"Resar","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"2022050515305488700_B30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat Genet."},{"issue":"11","key":"2022050515305488700_B31","doi-asserted-by":"crossref","first-page":"e48533","DOI":"10.1371\/journal.pone.0048533","article-title":"HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks","volume":"7","author":"Shah","year":"2012","journal-title":"PLoS One."},{"issue":"3","key":"2022050515305488700_B32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/cr.2011.12","article-title":"Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures","volume":"21","author":"Chou","year":"2011","journal-title":"Cell Res."},{"issue":"1","key":"2022050515305488700_B33","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/ncomms15008","article-title":"HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche","volume":"8","author":"Xian","year":"2017","journal-title":"Nat Commun."},{"issue":"1-2","key":"2022050515305488700_B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0167-4781(01)00215-9","article-title":"HMGI\/Y proteins: flexible regulators of transcription and chromatin structure","volume":"1519","author":"Reeves","year":"2001","journal-title":"Biochim Biophys Acta."},{"issue":"6870","key":"2022050515305488700_B35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/415436a","article-title":"Prediction of central nervous system embryonal tumour outcome based on gene expression","volume":"415","author":"Pomeroy","year":"2002","journal-title":"Nature."},{"issue":"2","key":"2022050515305488700_B36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/path.1960","article-title":"Increased expression of high mobility group A proteins in lung cancer","volume":"209","author":"Sarhadi","year":"2006","journal-title":"J Pathol."},{"issue":"9","key":"2022050515305488700_B37","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/0008-5472.CAN-05-1684","article-title":"The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis","volume":"67","author":"Tesfaye","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"2022050515305488700_B38","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1158\/1541-7786.MCR-08-0336","article-title":"Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer","volume":"7","author":"Hillion","year":"2009","journal-title":"Mol Cancer Res."},{"issue":"1","key":"2022050515305488700_B39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/modpathol.2009.139","article-title":"HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma","volume":"23","author":"Hristov","year":"2010","journal-title":"Mod Pathol."},{"issue":"4","key":"2022050515305488700_B40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pan.2012.05.005","article-title":"The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma","volume":"12","author":"Hillion","year":"2012","journal-title":"Pancreatology."},{"issue":"5","key":"2022050515305488700_B41","doi-asserted-by":"crossref","first-page":"e63419","DOI":"10.1371\/journal.pone.0063419","article-title":"HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2022050515305488700_B42","doi-asserted-by":"crossref","first-page":"e30034","DOI":"10.1371\/journal.pone.0030034","article-title":"HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells","volume":"7","author":"Belton","year":"2012","journal-title":"PLoS One."},{"issue":"3","key":"2022050515305488700_B43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ygyno.2016.03.020","article-title":"The high mobility group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives matrix metalloproteinase-2 (MMP-2) in a subset of tumors","volume":"141","author":"Hillion","year":"2016","journal-title":"Gynecol Oncol."},{"issue":"1","key":"2022050515305488700_B44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-019-05419-1","article-title":"High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer","volume":"179","author":"Gorbounov","year":"2020","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"2022050515305488700_B45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0092-8674(92)90554-P","article-title":"The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene","volume":"71","author":"Thanos","year":"1992","journal-title":"Cell."},{"issue":"8","key":"2022050515305488700_B46","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/j.1460-2075.1993.tb05993.x","article-title":"SAR-dependent mobilization of histone H1 by HMG-I\/Y in\u00a0vitro: HMG-I\/Y is enriched in H1-depleted chromatin","volume":"12","author":"Zhao","year":"1993","journal-title":"EMBO J."},{"issue":"4","key":"2022050515305488700_B47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(94)90502-9","article-title":"Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold","volume":"76","author":"Saitoh","year":"1994","journal-title":"Cell."},{"issue":"17","key":"2022050515305488700_B48","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1021\/bi00183a043","article-title":"Short peptide fragments derived from HMG-I\/Y proteins bind specifically to the minor groove of DNA","volume":"33","author":"Geierstanger","year":"1994","journal-title":"Biochemistry."},{"issue":"7","key":"2022050515305488700_B49","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0092-8674(95)90136-1","article-title":"Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome","volume":"83","author":"Thanos","year":"1995","journal-title":"Cell."},{"issue":"7","key":"2022050515305488700_B50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/0092-8674(95)90137-X","article-title":"Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y)","volume":"83","author":"Falvo","year":"1995","journal-title":"Cell."},{"issue":"13","key":"2022050515305488700_B51","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1073\/pnas.93.13.6716","article-title":"Multivalent DNA-binding properties of the HMG-1 proteins","volume":"93","author":"Maher","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2022050515305488700_B52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nsb0897-657","article-title":"The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif","volume":"4","author":"Huth","year":"1997","journal-title":"Nat Struct Biol."},{"issue":"24","key":"2022050515305488700_B53","doi-asserted-by":"crossref","first-page":"10121","DOI":"10.1158\/0008-5472.CAN-08-2121","article-title":"The high-mobility group A1a\/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies?","volume":"68","author":"Hillion","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"2022050515305488700_B54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/1471-2164-12-549","article-title":"HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis","volume":"12","author":"Schuldenfrei","year":"2011","journal-title":"BMC Genomics."},{"issue":"10","key":"2022050515305488700_B55","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-04-0044","article-title":"The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia","volume":"64","author":"Xu","year":"2004","journal-title":"Cancer Res."},{"issue":"8","key":"2022050515305488700_B56","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3109\/10428194.2013.764422","article-title":"Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis","volume":"54","author":"Di Cello","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"11","key":"2022050515305488700_B57","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3109\/10428194.2013.782610","article-title":"HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia","volume":"54","author":"Roy","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"15","key":"2022050515305488700_B58","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1128\/MCB.20.15.5490-5502.2000","article-title":"HMG-I\/Y, a new c-Myc target gene and potential oncogene","volume":"20","author":"Wood","year":"2000","journal-title":"Mol Cell Biol."},{"issue":"15","key":"2022050515305488700_B59","first-page":"4256","article-title":"The oncogenic properties of the HMG-I gene family","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res."},{"issue":"10","key":"2022050515305488700_B60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3109\/10428194.2011.591012","article-title":"Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia","volume":"52","author":"Nelson","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"2022050515305488700_B61","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2010-09-310862","article-title":"Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias","volume":"117","author":"Karp","year":"2011","journal-title":"Blood."},{"issue":"7831","key":"2022050515305488700_B62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature."},{"issue":"7351","key":"2022050515305488700_B63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10163","article-title":"A conditional knockout resource for the genome-wide study of mouse gene function","volume":"474","author":"Skarnes","year":"2011","journal-title":"Nature."},{"issue":"10","key":"2022050515305488700_B64","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood."},{"issue":"6","key":"2022050515305488700_B65","doi-asserted-by":"crossref","first-page":"e0232801","DOI":"10.1371\/journal.pone.0232801","article-title":"Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera","volume":"15","author":"Spivak","year":"2020","journal-title":"PLoS One."},{"issue":"1","key":"2022050515305488700_B66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.a.22093","article-title":"Flow cytometry analysis of murine hematopoietic stem cells","volume":"83","author":"Mayle","year":"2013","journal-title":"Cytometry A."},{"issue":"7","key":"2022050515305488700_B67","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1084\/jem.20160806","article-title":"Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization","volume":"214","author":"Freitas","year":"2017","journal-title":"J Exp Med."},{"issue":"50","key":"2022050515305488700_B68","doi-asserted-by":"crossref","first-page":"31945","DOI":"10.1073\/pnas.2017626117","article-title":"Prdm16 is a critical regulator of adult long-term hematopoietic stem cell quiescence","volume":"117","author":"Gudmundsson","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2022050515305488700_B69","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods."},{"issue":"3","key":"2022050515305488700_B70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol Cell."},{"issue":"6","key":"2022050515305488700_B71","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell."},{"issue":"6","key":"2022050515305488700_B72","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.molcel.2020.10.012","article-title":"Two aldehyde clearance systems are essential to prevent lethal formaldehyde accumulation in mice and humans","volume":"80","author":"Dingler","year":"2020","journal-title":"Mol Cell."},{"issue":"6","key":"2022050515305488700_B73","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood.V72.6.1968.1968","article-title":"Characterization of a new megakaryocytic cell line: the Dami cell","volume":"72","author":"Greenberg","year":"1988","journal-title":"Blood."},{"issue":"12","key":"2022050515305488700_B74","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2400868","article-title":"Identity of original and late passage Dami megakaryocytes with HEL erythroleukemia cells shown by combined cytogenetics and DNA fingerprinting","volume":"11","author":"MacLeod","year":"1997","journal-title":"Leukemia."},{"issue":"3","key":"2022050515305488700_B75","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"Quentmeier","year":"2006","journal-title":"Leukemia."},{"issue":"2","key":"2022050515305488700_B76","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6","article-title":"Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report","volume":"88","author":"Fiedler","year":"2000","journal-title":"Cancer."},{"issue":"43","key":"2022050515305488700_B77","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2022050515305488700_B78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"12","key":"2022050515305488700_B79","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","article-title":"CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles","volume":"7","author":"Zini","year":"2017","journal-title":"Blood Cancer J."},{"issue":"7","key":"2022050515305488700_B80","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.cell.2015.11.013","article-title":"Transcriptional heterogeneity and lineage commitment in myeloid progenitors","volume":"163","author":"Paul","year":"2015","journal-title":"Cell."},{"issue":"7","key":"2022050515305488700_B81","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41556-018-0121-4","article-title":"Single-cell characterization of haematopoietic progenitors and their trajectories in homeostasis and perturbed haematopoiesis","volume":"20","author":"Giladi","year":"2018","journal-title":"Nat Cell Biol."},{"issue":"7765","key":"2022050515305488700_B82","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature."},{"issue":"4","key":"2022050515305488700_B83","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41588-020-0595-4","article-title":"DNA methylation disruption reshapes the hematopoietic differentiation landscape","volume":"52","author":"Izzo","year":"2020","journal-title":"Nat Genet."},{"issue":"6494","key":"2022050515305488700_B84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/371221a0","article-title":"An early haematopoietic defect in mice lacking the transcription factor GATA-2","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature."},{"issue":"18","key":"2022050515305488700_B85","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/bloodadvances.2020002953","article-title":"Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?","volume":"4","author":"Bresnick","year":"2020","journal-title":"Blood Adv."},{"issue":"18","key":"2022050515305488700_B86","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1128\/MCB.00482-09","article-title":"GATA-2 reinforces megakaryocyte development in the absence of GATA-1","volume":"29","author":"Huang","year":"2009","journal-title":"Mol Cell Biol."},{"issue":"1","key":"2022050515305488700_B87","doi-asserted-by":"crossref","first-page":"12212","DOI":"10.1038\/s41598-019-48589-0","article-title":"Inhibition of GATA2 restrains cell proliferation and enhances apoptosis and chemotherapy mediated apoptosis in human GATA2 overexpressing AML cells","volume":"9","author":"Menendez-Gonzalez","year":"2019","journal-title":"Sci Rep."},{"issue":"17","key":"2022050515305488700_B88","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood."},{"issue":"2","key":"2022050515305488700_B89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell."},{"issue":"17","key":"2022050515305488700_B90","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022050515305488700_B91","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI82905","article-title":"Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis","volume":"127","author":"Gilles","year":"2017","journal-title":"J Clin Invest."},{"issue":"6","key":"2022050515305488700_B92","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1038\/bcj.2017.51","article-title":"The thrombopoietin\/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature","volume":"7","author":"Zingariello","year":"2017","journal-title":"Blood Cancer J."},{"issue":"3","key":"2022050515305488700_B93","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)62056-1","article-title":"Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis","volume":"167","author":"Vannucchi","year":"2005","journal-title":"Am J Pathol."},{"issue":"1","key":"2022050515305488700_B94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell."},{"issue":"22","key":"2022050515305488700_B95","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3\u2032UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood."},{"issue":"7","key":"2022050515305488700_B96","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2016-12-757344","article-title":"Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-\u03b21 and Cxcl12 pathways","volume":"130","author":"Dutta","year":"2017","journal-title":"Blood."},{"issue":"15","key":"2022050515305488700_B97","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2017004457","article-title":"Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms","volume":"1","author":"Ueda","year":"2017","journal-title":"Blood Adv."},{"issue":"8","key":"2022050515305488700_B98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-018-0103-6","article-title":"High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia","volume":"8","author":"Marquis","year":"2018","journal-title":"Blood Cancer J."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/18\/2797\/1895455\/bloodbld2021013925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/18\/2797\/1895455\/bloodbld2021013925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T11:32:41Z","timestamp":1651750361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/18\/2797\/484396\/HMGA1-chromatin-regulators-induce-transcriptional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":98,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013925","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}